84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]戎義發(fā),姜凱,賈海峰,等.炎癥因子與強(qiáng)直性脊柱炎及血液代謝物因果關(guān)系的孟德爾隨機(jī)化分析[J].中醫(yī)正骨,2024,36(11):26-41.
　RONG Yifa,JIANG Kai,JIA Haifeng,et al.The causal relationships of inflammatory factors with ankylosing spondylitis and blood metabolites:a mendelian randomization analysis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2024,36(11):26-41.
點(diǎn)擊復(fù)制

炎癥因子與強(qiáng)直性脊柱炎及血液代謝物因果關(guān)系的孟德爾隨機(jī)化分析()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第36卷
期數(shù):
2024年11期
頁碼:
26-41
欄目:
數(shù)據(jù)庫研究
出版日期:
2024-11-20

文章信息/Info

Title:
The causal relationships of inflammatory factors with ankylosing spondylitis and blood metabolites:a mendelian randomization analysis
作者:
戎義發(fā)1; 姜凱1; 賈海峰1; 李翰政1; 李樹棟1; 李剛2
1.山東中醫(yī)藥大學(xué)第一臨床醫(yī)學(xué)院,山東 濟(jì)南 250014; 2.山東中醫(yī)藥大學(xué)附屬醫(yī)院,山東 濟(jì)南 250014
Author(s):
RONG Yifa1; JIANG Kai1; JIA Haifeng1; LI Hanzheng1; LI Shudong1; LI Gang2
1.The First Clinical Medical College of Shandong University of Traditional Chinese Medicine,Jinan 250014,Shandong,China 2.The Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250014,Shandong,China
關(guān)鍵詞:
脊柱炎; 強(qiáng)直性;  炎癥介導(dǎo)素類;  代謝物;  孟德爾隨機(jī)化分析
Keywords:
spondylitis; ankylosing;  inflammation mediators;  metabolites;  Mendelian randomization analysis
摘要:
目的:探討炎癥因子與強(qiáng)直性脊柱炎(ankylosing spondylitis,AS)及血液代謝物的因果關(guān)系。方法:從全基因組關(guān)聯(lián)研究(genome-wide association study,GWAS)Catalog數(shù)據(jù)庫中獲取炎癥因子表達(dá)水平和血液代謝物指標(biāo)(代謝物水平或代謝物比率)的GWAS數(shù)據(jù),從FinnGen數(shù)據(jù)庫中獲取AS的GWAS數(shù)據(jù)。基于工具變量篩選標(biāo)準(zhǔn),篩選符合要求的炎癥因子表達(dá)水平的單核苷酸多態(tài)性(single nucleotide polymorphism,SNP)位點(diǎn)。將篩選出的炎癥因子表達(dá)水平的SNP位點(diǎn)作為工具變量,以AS為結(jié)局進(jìn)行孟德爾隨機(jī)化(Mendelian randomization,MR)分析,并進(jìn)行敏感性分析; 將確定的與AS具有可靠因果關(guān)系的炎癥因子表達(dá)水平的SNP位點(diǎn)作為工具變量,以血液代謝物指標(biāo)為結(jié)局進(jìn)行MR分析,并進(jìn)行敏感性分析。結(jié)果:①炎癥因子表達(dá)水平與AS的因果關(guān)系分析結(jié)果。CD244、成纖維細(xì)胞生長因子(fibroblast growth factor,FGF)-23、FMS樣酪氨酸激酶3配體(FMS-like tyrosine kinase 3 ligand,FIt3L)、白細(xì)胞介素(interleukin,IL)-7表達(dá)水平與AS存在可靠的因果關(guān)系,其中CD244、FIt3L表達(dá)水平與AS呈負(fù)相關(guān),FGF-23、IL-7表達(dá)水平與AS呈正相關(guān)。②炎癥因子表達(dá)水平與血液代謝物指標(biāo)的因果關(guān)系分析結(jié)果。CD244、FGF-23、FIt3L、IL-7表達(dá)水平分別與61項(xiàng)、62項(xiàng)、37項(xiàng)、68項(xiàng)血液代謝物指標(biāo)存在可靠的因果關(guān)系。結(jié)論:FGF-23、IL-7、CD244、FIt3L表達(dá)水平與AS存在可靠的因果關(guān)系,這4種炎癥因子表達(dá)水平分別與多項(xiàng)血液代謝物指標(biāo)存在可靠的因果關(guān)系; 這為探索AS的發(fā)生機(jī)制和治療AS的藥物靶點(diǎn)提供了參考。
Abstract:
Objective:To explore the causal relationships of inflammatory factors with ankylosing spondylitis(AS)and blood metabolites.Methods:The genome-wide association study(GWAS)data about the expression levels of inflammatory factors and blood metabolite indicators(metabolite levels or metabolite ratios)were retrieved and extracted from the GWAS Catalog database,and that about AS from the FinnGen database.According to the instrumental variable screening criteria,the eligible single nucleotide polymorphism(SNP)loci for the expression levels of inflammatory factors were screened as the instrumental variable,and then a mendelian randomization(MR)analysis was conducted with AS as the outcome variable to assess the causality between the expression levels of inflammatory factors and AS,and the sensitivity was examined.Furthermore,another MR analysis was conducted by taking the SNP loci of the expression levels of inflammatory factor having a reliable causality with AS as the instrumental variable,and the blood metabolite indicators as the outcome variable to assess the causality between the expression levels of inflammatory factors and blood metabolite indicators,and the sensitivity was examined.Results:①The causality between the expression levels of inflammatory factors and AS.The expression levels of CD244,fibroblast growth factor(FGF)-23,FMS-like tyrosine kinase 3 ligand(FIt3L)and interleukin(IL)-7 exhibited a reliable causal relationship with AS,among which,the expression levels of CD244 and FIt3L showed a inverse causal relationship with AS,while the expression levels of FGF-23 and IL-7 presented a positive causal relationship with AS.②The causality between the expression levels of inflammatory factors and blood metabolite indicators.The expression levels of CD244,FGF-23,FIt3L and IL-7 exhibited a reliable causal relationship with 61,62,37 and 68 blood metabolite indicators,respectively.Conclusion:The expression levels of FGF-23,IL-7,CD244 and FIt3L exhibit a reliable causal relationship with AS,and they also have a reliable causal relationship with multiterm blood metabolite indicators,respectively,which provides a reference for exploring the pathogenesis of AS and the potential drug targets in treating AS.

參考文獻(xiàn)/References:

[1] TAUROG J D,CHHABRA A,COLBERT R A.Ankylosing spondylitis and axial spondyloarthritis[J].N Engl J Med,2016,374(26):2563-2574.
[2] DEAN L E,JONES G T,MACDONALD A G,et al.Global prevalence of ankylosing spondylitis[J].Rheumatology(Oxford),2014,53(4):650-657.
[3] EXARCHOU S,LINDSTROM U,ASKLING J,et al.The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations:a nationwide register study[J].Arthritis Res Ther,2015,17(1):118.
[4] TAM L S,GU J,YU D.Pathogenesis of ankylosing spondylitis[J].Nat Rev Rheumatol,2010,6(7):399-405.
[5] FURUE K,ITO T,FURUE M.Differential efficacy of biolo-gic treatments targeting the TNF-alpha/IL-23/IL-17 axis in psoriasis and psoriatic arthritis[J].Cytokine,2018,111:182-188.
[6] SIEPER J,PODDUBNYY D,MIOSSEC P.The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis[J].Nat Rev Rheumatol,2019,15(12):747-757.
[7] GENRE F,LOPEZ-MEJIAS R,MIRANDA-FILLOY J A,et al.Adipokines,biomarkers of endothelial activation,and metabolic syndrome in patients with ankylosing spondylitis[J].Biomed Res Int,2014,2014:860651.
[8] WALKER V M,ZHENG J,GAUNT T R,et al.Phenotypic causal inference using genome-wide association study data:Mendelian randomization and beyond[J].Annu Rev Biomed Data Sci,2022,5:1-17.
[9] ZHAO J H,STACEY D,ERIKSSON N,et al.Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets[J].Nat Immunol,2023,24(9):1540-1551.
[10] CHEN Y,LU T,PETTERSSON-KYMMER U,et al.Geno-mic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases[J].Nat Genet,2023,55(1):44-53.
[11] SWANSON C,SHEA S A,WOLFE P,et al.24-hour profile of serum sclerostin and its association with bone biomarkers in men[J].Osteoporos Int,2017,28(11):3205-3213.
[12] CELIK E,GUZEL S,ABALI R,et al.The relationship between fibroblast growth factor 23 and osteoporosis in post-menopausal women[J].Minerva Med,2013,104(5):497-504.
[13] YUN Z,GUO Z,LI X,et al.Genetically predicted 486 blood metabolites in relation to risk of colorectal cancer:a Mendelian randomization study[J].Cancer Med,2023,12(12):13784-13799.
[14] YANG M,WAN X,ZHENG H,et al.No evidence of a gene-tic causal relationship between ankylosing spondylitis and gut microbiota:a two-sample Mendelian randomization study[J].Nutrients,2023,15(4):1057.
[15] CAO Z,WU Y,LI Q,et al.A causal relationship between childhood obesity and risk of osteoarthritis:results from a two-sample Mendelian randomization analysis[J].Ann Med,2022,54(1):1636-1645.
[16] FURST D E,LOUIE J S.Targeting inflammatory pathways in axial spondyloarthritis[J].Arthritis Res Ther,2019,21(1):135.
[17] ZHU W,HE X,CHENG K,et al.Ankylosing spondylitis:etiology,pathogenesis,and treatments[J].Bone Res,2019,7:22.
[18] MIRZA M A,KARLSSON M K,MELLSTROM D,et al.Se-rum fibroblast growth factor-23(FGF-23)and fracture risk in elderly men[J].J Bone Miner Res,2011,26(4):857-864.
[19] LIMA F,MONIER-FAUGERE M C,MAWAD H,et al.FGF-23 and sclerostin in serum and bone of CKD patients[J].Clin Nephrol,2023,99(5):209-218.
[20] GERCIK O,SOLMAZ D,COBAN E,et al.Evaluation of se-rum fibroblast growth factor-23 in patients with axial spondyloarthritis and its association with sclerostin,inflammation,and spinal damage[J].Rheumatol Int,2019,39(5):835-840.
[21] KIM G Y,HONG C,PARK J H.Seeing is believing:illuminating the source of in vivo interleukin-7[J].Immune Netw,2011,11(1):1-10.
[22] CHEN D,TANG T X,DENG H,et al.Interleukin-7 biology and its effects on immune cells:mediator of generation,differentiation,survival,and homeostasis[J].Front Immunol,2021,12:747324.
[23] MEYER A,PARMAR P J,SHAHRARA S.Significance of IL-7 and IL-7R in RA and autoimmunity[J].Autoimmun Rev,2022,21(7):103120.
[24] CICCIA F,GUGGINO G,RIZZO A,et al.Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut,in the peripheral blood,synovial fluid and bone marrow of patients with ankylosing spondylitis[J].Ann Rheum Dis,2015,74(9):1739-1747.
[25] SUN L,GANG X,LI Z,et al.Advances in understanding the roles of CD244(SLAMF4)in immune regulation and associated diseases[J].Front Immunol,2021,12:648182.
[26] RAMOS M I,PEREZ S G,AARRASS S,et al.FMS-related tyrosine kinase 3 ligand(Flt3L)/CD135 axis in rheumatoid arthritis[J].Arthritis Res Ther,2013,15(6):R209.
[27] LI H,WANG L,ZHU J,et al.Diagnostic serum biomarkers associated with ankylosing spondylitis[J].Clin Exp Med,2023,23(5):1729-1739.
[28] VITTIMBERGA F J,MCDADE T P,PERUGINI R A,et al.Sodium salicylate inhibits macrophage TNF-alpha production and alters MAPK activation[J].J Surg Res,1999,84(2):143-149.
[29] ZU L,JIANG H,HE J,et al.Salicylate blocks lipolytic actions of tumor necrosis factor-alpha in primary rat adipocytes[J].Mol Pharmacol,2008,73(1):215-223.
[30] PAINE A,BROOKES P S,BHATTACHARYA S,et al.Dy-sregulation of bile acids,lipids,and nucleotides in psoriatic arthritis revealed by unbiased profiling of serum metabolites[J].Arthritis Rheumatol,2023,75(1):53-63.
[31] NYSTROM N,PRAST-NIELSEN S,CORREIA M,et al.Mucosal and plasma metabolomes in new-onset paediatric inflammatory bowel disease:correlations with disease characteristics and plasma inflammation protein markers[J].J Crohns Colitis,2023,17(3):418-432.
[32] ZHANG Y H,WANG J,DONG G H,et al.Mechanism of perfluorooctanesulfonate(PFOS)-induced apoptosis in the immunocyte[J].J Immunotoxicol,2013,10(1):49-58.
[33] ZHANG J,WU G,ZHU H,et al.Circulating carnitine levels and breast cancer:a matched retrospective case-control study[J].Front Oncol,2022,12:891619.
[34] LIU J,GENG W,SUN H,et al.Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma[J].Gut,2022,71(6):1203-1213.
[35] SIDOR K,JEZNACH A,HOSER G,et al.1-Methylnicotinamide(1-MNA)inhibits the activation of the NLRP3 inflammasome in human macrophages[J].Int Immunopharmacol,2023,121:110445.
[36] HOU G,XU W,DING D,et al.Metabolome and transcriptome integration reveals metabolic profile of hepatocellular carcinoma[J].J Gastroenterol Hepatol,2022,37(12):2321-2330.
[37] MOORE S C,PLAYDON M C,SAMPSON J N,et al.A metabolomics analysis of body mass index and postmenopausal breast cancer risk[J].J Natl Cancer Inst,2018,110(6):588-597.
[38] IMRICH R,ROVENSKY J,ZLNAY M,et al.Hypothalamic-pituitary-adrenal axis function in ankylosing spondylitis[J].Ann Rheum Dis,2004,63(6):671-674.
[39] KIRNAP M,ATMACA H,TANRIVERDI F,et al.Hypothalamic-pituitary-adrenal axis in patients with ankylosing spondylitis[J].Hormones(Athens),2008,7(3):255-258.
[40] FANG P,LIU X,QIU Y,et al.Exploring causal correlations between inflammatory cytokines and ankylosing spondylitis:a bidirectional mendelian-randomization study[J].Front Immunol,2023,14:1285106.

相似文獻(xiàn)/References:

[1]閻曉霞,任之強(qiáng),仝允輝,等.布魯氏菌性脊柱炎3例[J].中醫(yī)正骨,2015,27(06):64.
[2]趙偉光,劉振武,劉利,等.強(qiáng)直性脊柱炎合并右側(cè)股骨頭和股骨頸骨溶解癥1例[J].中醫(yī)正骨,2015,27(01):75.
[3]黃建武,黃建華,黃影.腫瘤壞死因子-α在強(qiáng)直性脊柱炎活動期患者中的表達(dá)[J].中醫(yī)正骨,2013,25(11):22.
[4]張董喆,孔超,張建福.針刺夾脊穴結(jié)合督灸治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2014,26(07):58.
[5]吳建國.強(qiáng)直性脊柱炎并發(fā)脊柱骨折的影像學(xué)表現(xiàn)[J].中醫(yī)正骨,2013,25(06):31.
[6]謝國華,薛峰,楊建平,等.強(qiáng)直性脊柱炎脊柱應(yīng)力性骨折的診斷[J].中醫(yī)正骨,2012,24(12):72.
[7]張萬義,張永紅,王笑青.雙醋瑞因膠囊聯(lián)合柳氮磺胺吡啶腸溶片與右旋布洛芬膠囊治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2012,24(06):26.
　ZHANG Wan-yi*,ZHANG Yong-hong,WANG Xiao-qing.*.Study on the curative effects of diacerein capsules combined with sulfasalazine enteric-coated tablets and dextral ibuprofen capsules in the treatment of ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(11):26.
[8]黃建華,黃建武,陳金春,等.早期強(qiáng)直性脊柱炎血管內(nèi)皮生長因子、C反應(yīng)蛋白 表達(dá)水平的臨床研究[J].中醫(yī)正骨,2012,24(02):9.
　HUANG Jian-hua*,HUANG Jian-wu,CHEN Jin-chun,et al.Clinical research on the expression of VEGF、CRP in early ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(11):9.
[9]王笑青,張永紅,王玉麗,等.常規(guī)藥物口服配合中藥離子導(dǎo)入治療強(qiáng)直性脊柱炎肌腱附著點(diǎn)炎[J].中醫(yī)正骨,2011,23(10):18.
　WANG Xiao-qing*,ZHANG Yong-hong,WANG Yu-li,et al.A study on the curative effects of oral conventional drugs combined with traditional Chinese medicine iontophoresis on ankylosing spondylitis tendon enthesitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(11):18.
[10]劉紅軍.單節(jié)段楔形截骨結(jié)合椎弓根A-F系統(tǒng)內(nèi)固定 治療強(qiáng)直性脊柱炎脊柱后凸畸形[J].中醫(yī)正骨,2011,23(09):65.
[11]戴霞華,李寅潔.指導(dǎo)性功能鍛煉在兒童強(qiáng)直性脊柱炎護(hù)理中的應(yīng)用[J].中醫(yī)正骨,2015,27(10):78.
[12]張夢雨,鮑鐵周,田江波.督脈隔姜灸聯(lián)合柳氮磺吡啶腸溶片口服及 功能鍛煉治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2015,27(09):44.
[13]赫軍,諸葛天諭,李冬冬,等.中藥內(nèi)服聯(lián)合針刺與埋針法治療幼年強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2016,28(01):41.
[14]赫軍,諸葛天諭,李冬冬,等.四聯(lián)療法治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2016,28(06):50.
[15]張遂連,袁星星.自我管理在強(qiáng)直性脊柱炎患者門診護(hù)理中的應(yīng)用[J].中醫(yī)正骨,2017,29(03):79.
[16]李現(xiàn)林,薛華珍,陳星,等.口服通痹舒筋丸治療強(qiáng)直性脊柱炎寒濕痹阻證[J].中醫(yī)正骨,2017,29(05):31.
[17]龔家川.影響強(qiáng)直性脊柱炎患者髖關(guān)節(jié)受累的危險(xiǎn)因素分析[J].中醫(yī)正骨,2017,29(06):25.
　GONG Jiachuan.Analysis of risk factors for affection of hip joint in patients with ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(11):25.
[18]黃小龍,全仁夫,胡華輝,等.HLA-B2704基因型強(qiáng)直性脊柱炎患者來源的人誘導(dǎo)多能干細(xì)胞體系的建立[J].中醫(yī)正骨,2017,29(12):11.
　HUANG Xiaolong,QUAN Renfu,HU Huahui,et al.Establishment of human-induced pluripotent stem cells system originated from patients with HLA-B2704 genotypic ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(11):11.
[19]李洛宜,張依山,王笑青,等.系列化視頻在強(qiáng)直性脊柱炎健康教育中的應(yīng)用[J].中醫(yī)正骨,2018,30(03):78.
[20]任偉凡,胡勁濤,全仁夫,等.強(qiáng)直性脊柱炎易感基因的相關(guān)研究進(jìn)展[J].中醫(yī)正骨,2019,31(04):48.

備注/Memo

備注/Memo:
通訊作者:李剛 E-mail:[email protected]
更新日期/Last Update: 1900-01-01